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Abstract 
Background: Antibody-dependent cellular cytotoxicity (ADCC), which mainly mediated by natural killer (NK) cells, 
may play a critical role in slowing human immunodeficiency virus type-1 (HIV-1) disease progression and protecting 
from HIV-1 infection. Besides classic NK cells, CD56+ T cells also have some NK cell-like properties, such as the large 
granular lymphocyte morphology and the capacity to destroy NK-sensitive target cells. However, little is known about 
the potentials of antibody-dependent CD56+ T cell responses and the association between antibody-dependent 
CD56+ T cell responses and HIV-1 disease progression.
Results: In the present study, we showed evidences that, in addition to NK cells, CD56+ T cells could generate 
degranulation upon CD16 cross-linking. Ex vivo study showed that FcγRIII (CD16)-mediated CD56+ T cell responses 
were distinctly induced by IgG antibody-bound P815 cells. Comparatively, CD56− T cells and invariant NKT (CD3+ 
6B11+) failed to induce antibody-dependent activation. Antibody-dependent CD56+ T cell responses were mainly 
ascribed to CD4/CD8 double negative subset and were functionally impaired in long-term HIV-1-infected former 
plasma donors, regardless of hepatitis C virus (HCV) coinfection status. Also, CD56+ T cell-mediated HIV-1-specific 
antibody-dependent responses were declined in men who have sex with men with HIV-1 infection over 3 years. 
Finally, we showed that matrix metalloprotease (MMP) inhibitor GM6001 could partially restored antibody-dependent 
CD56+ T cell responses of chronic HIV-1-infected subjects.
Conclusions: Our results suggested that CD56+ T cells could mediate ADCC responses and the responses were 
impaired in chronic HIV-1 infection.
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Background
Antibody-dependent cellular cytotoxicity (ADCC) is a 
combined immune responses involving both innate and 
adaptive immunity [1]. In human, ADCC is typically 
initiated by recognition of membrane-surface antigens 
FcγRIIIa (CD16) or FcγRIIc (CD32) of effector cells to 
the Fc region of IgG antibodies which binding to spe-
cific antigens on the surface of target cells [2, 3]. In the 
last decade, substantial evidences supported the cru-
cial role of ADCC activities in controlling HIV infec-
tion. For example, HIV-specific ADCC responses were 
reported detectable in all tested elite controllers and was 
significantly higher than in HIV viremic individuals, and 
ADCC activities were correlated with slowed progres-
sion to acquired immune deficiency syndrome (AIDS) 
in SIV-infected macaques [4–6]. The well-known Thai 
RV144 HIV vaccine trail showed 31% protection in pre-
venting HIV acquisition with induction of robust HIV-
specific ADCC responses [7–9]. In addition to NK cells, 
other types of circulating granulocytes, such as neutro-
phils, monocytes and macrophages, were also reported 
to mediate ADCC activity [10–14].
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CD56+ T cells, also termed CD3+ CD56+ NKT-like 
cells, comprise approximately 5–15% of peripheral circu-
lating T cells in human and express cell-surface molecule-
CD56, a typical marker for natural killer (NK) cells [15]. 
CD56+ T cells are also characterized by some NK cell-
like properties, such as the large granular lymphocyte 
morphology and the capacity to destroy NK-sensitive 
target cells [15, 16]. Compared with CD56+ T cells, the 
CD1d-restricted invariant NKT (iNKT) cells, which are 
characterized by expression of a specific T cell receptor 
(TCR) (Vα24-Jα18-Vβ11 in humans), also play an impor-
tant regulatory role in the innate and adaptive immune 
responses. These iNKT cells share partially phenotypic 
and functional properties with NK and CD56+ T cells 
[17]. CD56+ T cells were presumed to display proper-
ties of both NK cells and T cells and exhibited capacities 
of cytotoxicity and cytokine production in both MHC-
restricted and MHC-unrestricted manner. CD56+ T cells 
displayed an essential role in antiviral immune response, 
such as inhibiting HCV and HIV-1 replication in  vitro 
[18, 19]. However, little is known about the potentials 
of CD56+ T cells in mediating ADCC responses and 
the association between CD56+ T cell-mediated ADCC 
responses and HIV-1 disease progression.
In this study, ex  vivo ADCC activities mediated by 
CD56+ T cells were investigated in healthy versus 
chronic HIV-1 infected subjects and were compared with 
NK-mediated ADCC responses. Potenial factors that 
may influence ADCC activities, such as FcγR expression, 
CD56+ T subset distribution, and MMPs inhibitor, were 
also evaluated.
Results
CD16 cross‑linking triggered degranulation of CD56+ T 
cells
FcγRIIIa (CD16), a low-affinity receptor, could bind 
to the Fc region of IgG and trigger ADCC responses. 
Besides CD16, FcγRIIc (CD32) was also reported respon-
sible for ADCC effect [20, 21]. In this study, the frequen-
cies of CD16+ or CD32+ subsets in CD56+ T cells, 
CD3+ CD56+ NK cells and CD3+ CD56− T cells was 
identified and compared (Fig.  1a, b). As expected, a 
considerable percentage of CD56+ T cells was CD16+ 
CD56+ T cells (11.4 ± 8.1%), which was lower than the 
percentage on NK cells (60.2  ±  18.9%, P  <  0.001) but 
higher than on CD56− T cells (0.9 ± 0.5%, P < 0.001). On 
the contrary, the percentage of CD32+ CD56+ T cells 
was found very low (less than 2%) on all three cell popu-
lations (Fig. 1b). The expression of CD16 and CD32 was 
confirmed on single cell level by image analysis (Fig. 1c). 
Purified CD56+ T cells (Purity > 95%, Additional file 1: 
Fig. S1) were triggered to degranulate after cross-linking 
with anti-CD16 monoclonal Ab, but not with anti-CD32 
Ab (P  <  0.001, Fig.  1d, e). Taken together, these results 
indicated that CD56+ T cells expressed a considerable 
level of CD16 and could be triggered to degranulate after 
CD16 cross-linking.
CD56+ T cells could mediate ADCC responses
In order to extensively detect the capacity of CD56+ 
cells to mediate ADCC responses, peripheral blood 
mononuclear cells (PBMCs) were stimulated with P815 
cells coated with P815-specific antibodies (P815/Abs) 
and ADCC response was reflected by CD107a and 
interferon-γ (IFNγ) production of CD56+ T, CD56+ NK 
and CD56− T cells. As shown in Fig.  2a, b, IFN-γ and 
CD107a expression were dramatically elevated in P815/
Abs-stimulated CD56+ T and CD56+ NK cells com-
pared with CD56− T cells (P < 0.001 for all). In addition, 
CD56+ T cells expressed a significantly lower CD107a 
(P  <  0.001) while similar level of IFNγ when compared 
with CD56+ NK cells, indicating a weaker degranulation 
capacity of CD56+ T cells versus NK cells (Fig.  2b). In 
addition, ADCC response time between CD56+ T and 
CD56+ NK cells was compared by stimulating effec-
tor cells with P815/Abs for 2, 4 and 6 h respectively. As 
shown in Additional file  2: Fig. S2a and S2b, CD56+ T 
cells responded to antibody-dependent stimulation after 
6 h incubation, while NK cells usually responded after 4 h 
incubation, which was more quickly than CD56+ T cells.
It is speculated that conjugation of CD16 with Ab-
opsonized P815 cells led to down-regulation of CD16 
expression and a subsequent cascade of intracellular 
signal activation, triggering IFNγ and CD107a produc-
tion. In this study, we found that stimulation with Ab-
opsonized P815 cells led to a tremendous decrease of 
CD16+ population in CD56+ T cells and NK cells, but 
not in CD56− T subset (Fig. 2c), which was in accordance 
with their capacities to mediate ADCC response. Fur-
ther analysis revealed a significant correlation between 
MFI loss of CD16 and CD107a expression (r  =  0.618, 
P  <  0.001) in CD56+ T cell-mediated ADCC responses 
(Fig. 2d). In P815/Abs activated CD56+ T cells, CD107a 
expression was positively correlated with IFNγ secre-
tion (r = 0.919, P < 0.001, Fig. 2e), indicating that cellular 
degranulation and IFNγ production may share common 
signal activation pathway in ADCC activities mediated by 
CD56+ T cells.
To confirm the capacity of CD56+ T cells to medi-
ate ADCC responses, purified CD56+ T cells were co-
cultured with P815 cells or Ab-opsonized P815 cells, 
and supernatants were collected for IFNγ detection by 
ELISA. As shown in Fig. 2f, the levels of IFNγ were sig-
nificantly higher in cell supernatant stimulated with Ab-
coated p815 cells than with P815 cells alone (P < 0.001), 
confirming that peripheral CD56+ T cells possessed 
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the potential to mediate ADCC function. Moreover, 
to address antibody-dependent lytic capacity of puri-
fied CD56+ T cell, target P815 cells were pre-stained 
with PKH26 and CFSE, and a rapid fluorometric ADCC 
(RFADCC) assay was employed to detect the frequencies 
of CFSE−/low target cells (Fig.  2g). As shown in Fig.  2h, 
Fig. 1 Degranulation of CD56+ T cells could be triggered by CD16 cross-linking. a Gating strategies of CD56+ T, CD56+ NK, and CD56− T cells 
from lymphocytes in a representative subject. The percentages of CD16+ and CD32+ cells in different subsets were also shown. b Frequencies of 
CD16+ and CD32+ cells in CD56+ T, CD56+ NK, and CD56− T cells of healthy donors (n = 10). Data were shown as mean ± SD. c Images of CD3, 
CD56, CD16, and CD32 expression on CD56+ T, CD56+ NK, and CD56− T cells at single-cell level. Data was performed on an ImageStreamχ MarkII 
system. Images of three separate samples were performed with similar results. d Representative flow plots depicted the ability of purified CD56+ T 
cells to degranulate in response to CD16/CD32 cross-linking with anti-CD16, anti-CD32, or nonspecific isotype antibodies. Positive responses were 
reflected by shifted CD107a expression. e The frequencies of CD107a+ CD56+ T cells upon CD16 or CD32 cross-linking in healthy donors (n = 10). 
The horizontal bar indicated median values. All P values were two-tailed and considered significant when less than 0.05
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the percentage of lysed P815 target cells were higher in 
CD56+ T cells incubating with Ab-coated p815 cells 
than with P815 cells alone (P < 0.001). A similar trend of 
antibody-dependent lytic capacity was found in NK cells 
but not in CD56− T cells. Taken together, these results 
indicated that ADCC responses could be mediated by 
CD56+ T cells though the intensity was generally lower 
than the response mediated by classic CD56+ NK cells.
Invariant NKT failed to mediate ADCC responses
Peripheral iNKT is usually defined as CD3+ Vα24-Jα18+ 
double positive cells in lymphocytes. Initially, we 
detected the frequencies of CD16+, CD161+ [22] and 
CD69+ [23] (two markers of lymphocyte activation) 
cells in iNKT cells and CD56+ T cells from 10 healthy 
donors. As indicated in Fig. 3a, b, compared to CD56+ 
T cells, a significantly lower frequency of CD16+ iNKT 
cells were found (P = 0.006). No differences of CD161+ 
and CD69+ cells were presented between these two 
types of cells. Furthermore, the capacity of iNKT to 
mediate ADCC was evaluated by detecting the frequency 
of IFNγ+ cells using the strategy for ADCC detection 
above. Compared to CD56+ T cells, IFNγ-producing 
iNKT cells were extremely lower after stimulating with 
Ab-bound P815 cells (Fig.  3c). There was no significant 
difference in IFNγ production between iNKT cells stim-
ulated with P815 cells alone and Ab-bound P815 cells 
(P > 0.05), in contrast to CD56+ T cells which showed an 
dramatically increased IFNγ+ production after stimulat-
ing with Ab-bound P815 cells (P < 0.001) (Fig. 3d). These 
data demonstrated that, unlike CD56+ T cells, iNKT 
cells were unable to mediate ADCC responses.
CD56+ T cell‑mediated nonspecific ADCC was impaired 
in long‑term HIV‑1 infected FPDs
Nonspecific ADCC activity mediated by CD56+ T cells 
and CD56+ NK cells were evaluated in long-term HIV-
1-infected former plasma donors (FPDs) (n  =  76, of 
which 36 were coinfected with HCV) and healthy con-
trols (n = 36). Compared to healthy controls, CD56+ T 
cell-mediated nonspecific ADCC responses were sig-
nificantly lower in both HIV-1 monoinfected individu-
als (P < 0.001 for CD107a, and P = 0.048 for IFNγ) and 
HIV-1/HCV coinfected individuals (P < 0.001 for CD107a, 
and P = 0.008 for IFNγ), which was similar to the trends 
of ADCC mediated by CD56+ NK cells (P  <  0.001 for 
all) (Fig. 4a, b). The decreased ADCC activities might be 
ascribed to the functional impairment of CD56+ T cells, 
since the frequencies of CD56+ T cells were comparable 
among HIV-1 monoinfected subjects, HIV-1/HCV coin-
fected subjects, and healthy subjects (P > 0.05, Fig. 4c) and 
the frequency of CD16+ cells within CD56+ T-cells was 
even higher in HIV infected subjects than in healthy con-
trols (P = 0.018 for HIV-1 monoinfection and P = 0.003 
for HIV-1/HCV coinfection) (Fig.  4d). No differences 
were found between HIV-1 monoinfection and HIV-1/
HCV coinfection regarding to ADCC activities mediated 
by either CD56+ T or CD56+ NK cells, suggesting that 
HCV coinfection had no or negligible influence on non-
specific ADCC activities in HIV-1 infection.
In addition, the positive correlations between frequen-
cies of CD107a+ CD56+ T cells and MFI loss of CD16 
on CD56+ T cells still existed in both HIV-1-monoin-
fected (r = 0.545, P = 0.007) and HIV-1/HCV-coinfected 
(r = 0.658, P < 0.001) subjects (Fig. 4e). Similarly, positive 
correlations between frequencies of CD107a+ CD56+ T 
cells and IFNγ+ CD56+ T cells were presented in HIV-1 
monoinfection (r  =  0.335, P =  0.043) and HIV-1/HCV 
coinfection (r = 0.453, P = 0.018) (Fig. 4f ). These results 
indicated that CD56+ T cells sustained the balance of 
cytotoxicty and immune regulation, though with an 
impaired capacities to mediated immune responses. No 
significant correlation between CD56+ T cell-mediated 
ADCC activities and HIV-1 viral loads or CD4+ T cell 
counts were found (data not shown).
Taken together, these data suggested that HIV-1 infec-
tion impaired the capacity of nonspecific CD56+ T 
cells to mediate ADCC responses in long-term HIV-1+ 
subjects, while HCV coinfection did not aggravate the 
impairment.
(See figure on next page.) 
Fig. 2 Nonspecific ADCC responses mediated by CD56+ T,CD56+ NK and CD56− T cells. a Representative flow plots showing the capacities of 
CD56+ T,CD56+ NK and CD56− T cells to respond to P815 cells coated with P815-specific Abs (P815+ Ab), p815 cell alone, or medium. Positive 
ADCC responses were represented by increased CD107a expression and IFNγ secretion. b Nonspecific ADCC activities mediated by CD56+ T, 
CD56+ NK and CD56− T cells were evaluated in 36 healthy donors. The difference of percentage (P815/Ab minus P815) of CD107a+ and IFNγ+ 
cells in CD56+ T,CD56+ NK and CD56− T cells stimulated by Ab-bound P815 cells was shown. The horizontal bar indicated median values. c MFI 
loss (P815 minus P815/Ab) of CD16 on CD56+ T, CD56+ NK and CD56− T cells following stimulation with Ab-bound P815 cells. Horizontal bar indi-
cated median value. d MFI loss of CD16 was correlated with CD107a+ expression in CD56+ T cell-mediated nonspecific ADCC response. e CD107a 
expression was correlated with IFNγ production in CD56+ T cell-mediated nonspecific ADCC responses. f Purified CD56+ T cells were co-cultured 
with P815 cells or Ab-bound P815 cells for 24 h and levels of IFNγ in cell supernatants were detected by ELISA. g Representative flow plots showing 
lytic capacities of purified CD56+ T, NK, CD56-T cells co-cultured with P815 cells or Ab-bound P815 cells for 10 h. Target P815 cells were shown as 
PKH26+ cells and CFSE−/low target cells indicated lysed target cells. h The percentage of lysed target cells induced by CD56+ T, CD56+ NK and 
CD56− T cells in healthy donors (n = 10). All P values were two-tailed and considered significant when less than 0.05
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Fig. 3 Evaluation of nonspecific ADCC activity mediated by invariant NKT cells. a The representative flow plots indicated CD16, CD161 and CD69 
expression on human invariant NKT cells (iNKT, CD3+ 6B11+) and CD56+ T cellsrespectively. b Comparison of CD16, CD161 and CD69 expression 
on iNKT and CD56+ T cells from ten healthy donors. c The representative flow plots indicated IFNγ production by iNKT and CD56+ T cells stimu-
lated by Ab-bound P815 cells. d The frequencies of IFNγ+ iNKT and IFNγ+ CD56+ T cells from ten healthy donors in response to P815 cells alone or 
Ab-coated P815 cells. All P values were two-tailed and considered significant when less than 0.05
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HIV‑1‑specific ADCC activities mediated by CD56+ T cells 
were declined in MSM with HIV‑1 infection over 3 years
HIV-1-specific ADCC activities were evaluated in men 
who have sex with men (MSM) subjects with HIV-1-in-
fection for 1–3 years (n = 22) and over 3 years (n = 13). 
HIV-specific ADCC responses were identified by the 
frequencies of CD107a+ or IFNγ+ CD56+ T cells 
in response to HIV-1 specific peptide pools (Fig.  5a). 
In MSM with HIV-1-infection over 3  years, intracel-
lular IFNγ expression by CD56+ T cells was dramati-
cally declined in comparison with in subjects infected 
for 1-3  year (env: P  =  0.028, gag: P  =  0.008, and pol: 
P = 0.025, Fig. 5c). Though similar trends were found in 
the frequency of CD107a+ CD56+ T cells in response 
to individual peptide pool, no significant P values were 
reached (Fig.  5b). These data indicated that CD56+ T 
cell-mediated ADCC was impaired in chronic HIV-1-in-
fected subjects but not recently infected subjects, which 
was consistent with the impaired capacities of CD56+ 
T cells to mediate nonspecific ADCC responses in long-
time HIV-1 infected FPDs.
CD56+ T cells mediating ADCC activities were mainly CD4/
CD8 double negative subset
According to the surface expression of CD4 and CD8, 
CD56+ T cells could be divided into three subsets: 
CD4+ CD8− (CD4+ subset), CD4− CD8+ (CD8+ sub-
set), CD4− CD8− (double negative subset, DN) (Fig. 6a). 
In healthy subjects, the proportion of DN subset and 
CD8+ subset was similar, occupying appropriate 40% of 
total CD56+ T cells respectively, while the frequency of 
CD4+ subset was significantly lower than DN and CD8+ 
subsets (P  <  0.001, Fig.  6b). In long-term HIV-infected 
subjects, the frequency of CD4+ subset was significantly 
decreased (P = 0.007), while the frequency of CD8+ sub-
set was increased (P = 0.023) when compared to healthy 
controls (Fig. 6b). No difference in percentage of DN sub-
set was found between HIV-infected FPDs and healthy 
controls (P > 0.05, Fig. 6b).
Next, ADCC activities mediated by different CD56+ 
T subsets were evaluated. As shown in Fig.  6c, d, DN 
subset contributed to the highest CD107a expression 
(DN vs. CD8+: P = 0.004) and IFNγ production (DN vs. 
CD4+: P = 0.028; DN vs. CD8+: P = 0.004) in healthy 
controls, though CD16+ frequency was lower on DN 
subset compared with CD4+ subset (P < 0.001, Fig. 6e). 
In long-term HIV-1 infection, ADCC activities medi-
ated by DN CD56+ T subset were significantly declined 
(CD107a: P = 0.018; IFNγ: P = 0.010), indicating a func-
tional impairment of the subset (Fig. 6c, d). The favorable 
ADCC activities mediated by DN CD56+ T subset was 
confirmed by the most loss of CD16 (frequencies) on 
DN subset than CD8+ subsets in both HIV-1-infected 
subjects (P  =  0.026) and healthy controls (P  =  0.038) 
(Fig.  6f ). Of note, for HIV-1 infection, the characteris-
tics of CD4+ subset and its capacity to mediate ADCC 
responses were missed in the study due to a very low 
cells number resulting unreliable results. Taken together, 
these results suggested that ADCC response mediated 
by CD56+ T cells was mainly ascribed to DN subset and 
was significantly impaired in long-term HIV-1 infection.
Finally, in consideration of different performances of 
three subsets of CD56+ T in mediating ADCC activi-
ties, we evaluated the characteristics of CD56+ T sub-
sets in expressing NK cell-associated markers, including 
NKG2A, NKG2C, NKG2D, NKp44 and NKp46. The data 
showed a good consistency that the highest levels of acti-
vate receptor NKG2C, NKG2D, NKp44 and NKp46 were 
observed on CD8+ subset, and moderate on DN cells 
and the lowest on CD4+ subset (Fig. 6g). However, inhib-
itory receptor NKG2A was found highest on DN subset 
(P < 0.001) (Fig. 6g).
MMP inhibitor could partially restore CD56+ T cells 
mediated ADCC in long‑term HIV‑1 infected subjects
Activation of NK cells induces matrix metalloproteinase 
(MMP)-mediated cleavage of cell surface CD16 [24–26]. 
MMP inhibitor was reported to improve the ability of 
NK cells to mediate ADCC [27]. In this study, we found 
that CD16 MFI on DN CD16+ CD56+ T cells was lower 
in HIV+ patients versus healthy donors (P  =  0.005) 
(Fig.  7a) and could be reversed by GM6001 treatment 
for 3, 6 and 12 h (P < 0.001, Fig. 7b). To evaluate whether 
MMP inhibitor could improve CD56+ T cells mediated 
(See figure on next page.) 
Fig. 4 Nonspecific ADCC activities mediated by CD56+ T cells and CD56+ NK cells in long-term HIV-1-monoinfected FPDs, HIV-1/HCV-coinfected 
FPDs, and healthy donors. a Representative flow plots showed the levels of CD107a expression and IFNγ production from CD56+ T cells and 
CD56+ NK cells in HIV-1 infected subjects and healthy controls. b Comparison of percentages of CD107a+ (left panel) or IFNγ+ (right panel) cells in 
CD56+ T cells and CD56+ NK cells between HIV-1 infected subjects and healthy controls. c The frequencies of CD56+ T cells and CD56+ NK cells 
in peripheral lymphocytes in HIV-1 infected subjects and healthy controls. d The percentages of CD16+ cells in CD56+ T cells and CD56+ NK cells 
of HIV-1 infected subjects and healthy controls. e Correlations between the MFI loss of CD16 and expression of CD107a in CD56+ T cell-mediated 
nonspecific ADCC in HIV-1/HCV-coinfected (dash line) and HIV-1-monoinfected groups (solid line). f Correlations between CD107a expression and 
IFNγ production in CD56+ T cell-mediated nonspecific ADCC in HIV-1/HCV-coinfected (dash line) and HIV-1-monoinfected groups (solid line). The 
horizontal bar indicated median values. All P values were two-tailed and considered significant when lower than 0.05
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ADCC in HIV-1 infection, purified DN CD56+ T cells 
from 10 long-term HIV-1 infected patients were cul-
tured with Ab-coated P815 cells in the presence or 
absence of broad-spectrum MMP inhibitor GM6001. 
The results indicated that MMP blockade increased the 
intensity of degranulation as measured by percentage of 
CD107a+ cells (P =  0.004) and enhanced the secretion 
of IFNγ (P < 0.001) (Fig. 7c, d). Therefore, MMP inhibi-
tor treatment partially restored the impaired ADCC 
responses mediated by CD56+ T cells during long-term 
HIV-1 infection. In addition, we found GM6001 failed 
to enhance antibody-dependent CD56+ T response in 
healthy donors (data not shown), indicating that MMP 
inhibitor increases the potentials of CD56+ T cells to 
mediate antibody dependent responses only in a disease-
specific manner.
Discussion
Accumulated evidence showed that antibody-dependent 
cellular cytotoxicity may play an important role in the 
control of HIV-1 infection [28–32]. However, whether 
CD56+ T cells could act as effector cells to mediate 
Fig. 5 Comparisons of HIV-1-specific CD56+ T-mediated ADCC activity in men who have sex with men (MSM) with HIV-1 infection between 1 and 
3 years (n = 22) and >3 years (n = 13). a The representative flow plots indicated CD107a expression and IFNγ production by CD56+ T cells. HIV-
1-specific ADCC responses were compared between MSM with HIV-1 infection for 1–3 years and >3 years. Whole blood samples were incubated 
at 37 °C for 5 h with HIV-1 gag, pol, and env peptide pools respectively. HIV-1-specific ADCC responses were identified by expression of CD107a (b) 
and IFNγ (c) in CD56+ T cells. The horizontal bar indicated median values. All P values were two-tailed and considered significant when lower than 
0.05
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Fig. 6 ADCC activity mediated by CD56+ T cells were mainly ascribed to CD4/CD8 double negative subset. a CD56+ T cells were divided into 
three subsets: CD4+ CD8−, CD4− CD8+, and CD4− CD8− (double negative, DN) subsets. Representative flow plots from a HIV-infected individual 
and a healthy donor were shown. b Frequencies of different CD56+ T subsets in HIV-1+ (n = 10) and healthy (n = 10) subjects. c, d ADCC activities 
mediated by CD56+ T subset from HIV-1+ and healthy subjects were evaluated and compared. CD107a expression (c) and IFNγ production (d) of 
CD4+ CD8−, CD4− CD8+, and DN subset activated by Ab-bound P815 cells in HIV-1+ (n = 10) and healthy (n = 10) subjects were compared. 
e Comparison of CD16+ cells in individual CD56+ T subsets in HIV-1+ and healthy subjects. f Loss of CD16 MFI on different CD56+ T subsets in 
HIV-1+ and healthy subjects. g Expressions of NKG2A, NKG2C, NKG2D, NKp44 and NKp46 on three CD56+ T subsets from ten healthy subjects. MFI 
mean fluorescence intensity. b–g Data were showing as mean ± SD
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ADCC response is not clearly determined. CD56+ T cells 
were reported to produce large quantities of IFNγ and 
played an important role in natural outcome after expo-
sure to HIV-1 or HCV [33–35]. For example, Montoya 
et  al. reported that the frequencies of IFNγ-producing 
CD56+ T cells activated by PMA/ionomycin were sig-
nificantly higher in HIV-exposed seronegative (HESN) 
individuals than in chronic HIV-1-infected subjects 
[33]. In addition, IFNγ production stimulated by PMA/
ionomycin was much higher in CD56+ T cells than in 
NK cells and common CD3+ T cells [33]. Kokordelis 
et  al. demonstrated that activated CD56+ T cells could 
inhibit HCV replication in  vitro in an IFNγ-dependent 
manner [19]. Exposure to HCV has been associated 
with high level of IFNγ production and degranulation of 
CD56+ T cells [35, 36]. In the present study, we showed 
that CD56+ T cells have the capacity to degranulate 
after cross-linking with anti-CD16 antibody and could 
mediate ADCC responses in vitro. The characteristics of 
CD56+ T cell-mediated ADCC responses were some-
what different from ADCC activities mediated by classic 
CD56+ NK cells, since NK-mediated ADCC was marked 
by both powerful degranulation and IFNγ production 
while degranulation capacity was significantly weaker 
in CD56+ T cell-mediated ADCC though a comparable 
level of IFNγ production was observed.
iNKT cells was identified as CD3+ Vα24-Jα18(6B11)+ 
cells and responded to CD1d-restricted lipid ligands [37]. 
Different from CD56+ T cells, we found iNKT expressed 
less CD16 than CD56+ T cells and failed to response to 
Ab-coated P815 cells, indicating that iNKT was unable to 
mediate ADCC responses though shared some NK char-
acteristics. Another study has also found that iNKT cells 
did not mediated killing of neuroblastoma cell lines in 
the presence of a relevant antibody, although ADCC of 
mediated by NK cells was enhanced by activated iNKT 
Fig. 7 MMP inhibitor GM6001 partially restored the impaired ADCC capacity mediated by DN CD56+ T subset of HIV-1+ subjects. a CD16 MFI 
on DN CD16+ CD56+ T cells were compared between HIV+ patients (n = 10) and healthy controls (n = 10). b CD16 MFI on DN CD56+ T cells 
activated by IL-2+ DMSO and IL-2+ GM6001 for 0, 3, 6, 12 h. c CD107 expression and IFNγ production of DN subset from HIV+ patients (n = 10) 
activated by P815+ DMSO, P815+ Ab+ DMSO and P815+ Ab+ GM6001 were determined by flow cytometry. d The percentage of CD107a+ 
CD56+ T cells and IFNγ+ CD56+ T cells activated by Ab-bound P815 cells in the presence or absence of GM6001 from HIV-1+ subjects (n = 10)
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cells [38]. CD56+ T cells were heterozygous cell popula-
tion and could be subdivided into CD4+, CD8+, and DN 
subsets. Interestingly, unlike CD56− T cells, in which 
CD4+ or CD8+ single positive subset played the domi-
nant roles in mediating immune response, DN subset 
within CD56+ T cells occupied a dominant frequency of 
total CD56+ T cells and mediate the most robust ADCC 
activities. We speculated that DN subset was inclined 
to a NK-like function due to its negative expression of 
CD4 and CD8 and was unable to activate in a MHC-
dependent manner. In addition, nature killer cell recep-
tor (NKR) patterns were quite different among CD4+, 
CD8+, and DN subsets. CD4+ subset is characterized 
by the weakest expressions of NK cell-distinctive markers 
(NKG2A, NKG2C, NKG2D, NKp44 and Nkp46), which 
are expressed highest on CD8+ cells subset (except 
NKG2A), and then DN cells. The moderate frequencies 
of both CD16 and NK cell-specific markers may contrib-
ute to the highest ADCC activity mediated by DN subset.
In this study, we found the capacity of CD56+ T cells to 
mediate nonspecific ADCC function in long-term HIV-
infected FPDs was significantly weaker than in healthy 
controls. The decreased CD56+ T cell-mediated ADCC 
activities in HIV-1 infection might be ascribed to the 
functional impairment since the frequencies of CD56+ 
T cells were comparable among groups (Fig. 4c). In addi-
tion, frequencies of CD16+ CD56+ T cells were found 
higher in HIV-1 infected subjects, which was different 
from the reduced frequency of CD16+ NK cells in HIV-
1+ patients as reported previously and observed in this 
study [27, 39]. Considering that frequencies of CD16+ 
CD56+ T cells in DN subset was similar between HIV-1 
infected subjects and healthy control, increased frequen-
cies of CD16+ CD56+ subset in CD8+ CD56+ T cells 
was the main source of elevated CD16 on bulk CD56+ 
T cells in HIV-1+ subjects. Due to the loss of CD4+ T 
cells in HIV-1 infection, we also found a decreased fre-
quency of CD4+ CD56+ T cells in HIV-1 infection. 
As a result, the frequency of CD8+ CD56+ T cells was 
increased. However, CD8+ CD56+ T subset showed less 
capacity to mediate ADCC compared with DN subset. 
Combined the characteristics of less frequency, higher 
CD16 expression, moderated activate NKR expression, 
and highest ADCC activity of DN subset, we speculated 
that a balance between expression of surface CD16 and 
NKR might determine the ADCC capacities of different 
CD56+ T subsets.
Theoretically, nonspecific ADCC activities detected by 
Ab-opsonized P815 cells merely evaluated the potentials 
of effector cells to mediate degranulation and cytokine 
secretion, while failed to consider other important par-
ticipants involved in ADCC response, such as Ab factor. 
In this study, we employed a HIV-1-specific CD56+ T 
cell-mediated ADCC assay using whole blood samples 
incubating with HIV-1 peptide pools to identify HIV-
1-specific ADCC activities in HIV-1-infected individuals. 
Our data indicated that HIV-1-specific ADCC activity 
was also declined in MSM with HIV-1 infection longer 
than 3  years. To rule out TCR-dependent CD56+ T 
responses, whole blood samples used in HIV-1-specific 
ADCC assay were replaced by PBMCs samples. The 
results indicated that TCR-dependent CD56+ T cell 
responses (indicated by intracellular IFNγ production) 
were significantly lower than TCR-dependent CD56− T 
cell responses (Additional file 3: Fig. S3). The mean values 
of IFNγ producing CD56+ T cells stimulated by env, gag 
and env were all less than 0.2%, which were much lower 
than HIV antibody-dependent CD56+ T responses and 
could be ignored in the CD56+ T-mediated HIV-1-spe-
cific ADCC study. Moreover, the impaired ADCC activi-
ties mediated by CD56+ T cells may not only ascribe to 
the changes of phenotype, functionality and subset dis-
tribution of CD56+ T cells per se, but also associate with 
the alteration of titer, subclassand clonal natureof anti-
body involved in ADCC responses [5, 40–43].
Conclusions
In summary, our finding indicated that CD56+ T cells 
from long-term HIV-1-infected patients displayed 
weaker antibody-dependent capabilities of cytotoxic-
ity and IFNγ production. The impaired ADCC activi-
ties mediated by CD56+ T cells might represent a novel 
mechanism of dysregulated immune response in chronic 
HIV-1-infected patients, which shed light on the devel-




A total of 111 HIV-1-infected participants and 36 healthy 
controls were recruited in this study. Fasted venous blood 
samples were collected from each participant. Routine 
blood tests, clinical biomedical tests, and CD4 +/CD8+ 
T cell counts were performed by local CDC. Peripheral 
blood mononuclear cells (PBMCs) were prepared from 
fresh EDTA anti-coagulated peripheral blood using His-
topaque-1077 (Sigma, 10,771–500 ml) as described else-
where [21] and were stored (5  ×  106  cells per vial) in 
liquid nitrogen till use. Serum and EDTA anti-coagulated 
plasma were stored at −80 °C until use.
HIV-1 infection was screened by an ELISA assay (GBI 
Biotech, Beijing, China) for HIV antibody, and positive 
tests were confirmed by HIV Blot 2.2 WB assay (Genel-
abs Diagnostics, Singapore). The status of anti-HCV 
antibodies was determined using the ARCHITECT 
Anti-HCV System (Abbott Diagnostics, Abbott Park, 
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USA). Plasma level of HIV-1 RNA was measured with 
the Standard Amplicor HIV Monitor assay, version 2.0 
(Roche Diagnostics, Indianapolis, IN, USA), according to 
the manufacturer’s protocols. The lower limit of detec-
tion was 40 copies/ml. Plasma HCV RNA level was quan-
tified with 2nd Cobas Ampliprep/CobasTaqman (CAP/
CTM) HCV test system (Roche, Branchburg, NJ, USA) 
with a detection limit of 15 IU/ml.
FPDs and healthy controls
The study involved 76 anti-HIV-positive former plasma 
donors (FPDs) (Table 1), recruited from a village in cen-
tral China in July 2012. Among the 76 HIV-1+ individu-
als, 36 were coinfected with HCV and 40 were infected by 
HIV-1 alone. The infection time of these HIV-1+ patients 
was highly uniform (13–16  years), and all individuals 
were infected by a single closely related HIV-1 strain via 
unregulated commercial plasma donation practices in the 
late 1990s. HCV infection was characterized by positive 
anti-HCV response and positive results for HCV-RNA 
detection. All recruited subjects were negative for hepati-
tis B surface antigen (HBsAg) and had never received any 
forms of HCV-specific antiviral therapy. All HIV-1-pos-
itive FPDs had received regular or intermittent first-line 
antiretroviral therapy. 36 healthy adults from the same 
village who were negative for HBV/HCV/HIV-1 infection 
were recruited as controls (Table 1).
MSM
35 HIV-1 positive men who have sex with men (MSM) 
were recruited from Beijing city. Subjects were divided 
into two groups according to the length of HIV-1 infec-
tion: 1–3 years (n = 22) and >3 years (n = 13) (Table 2). 
All MSM subjects were naïve of antiretroviral therapy.
CD16/CD32 surface staining
To compare the surface expression of CD16 and CD32 on 
circulating CD56+ T cells, CD56+ NK cells and CD56− 
T cells, PBMCs from 10 healthy controls were stained 
with anti-CD3 Pacific Blue (clone UCHT1), anti-CD56 
PE-Cy7 (clone B159), anti-CD16 APC-Cy7 (clone 3G8), 
Table 1 Characteristics of HIV-1-infected former plasma donors (FPDs) and control individuals
* Number of cases (number/total in %)
†  Mean ± standard deviation (SD)
a Not applicable, b alanine aminotransferase, c aspartate aminotransferase
Characteristics HIV‑1‑monoinfected HIV‑1/HCV‑coinfected Healthy
Number 40 36 36
Female* 25 (62.5) 20 (55.6) 18 (50.0)
Age (years)† 43 (9.4) 44 (9.3) 46 (10.2)
Deduced infection time (years)† 15.1 (1.5) 14.8 (1.5) NAa
Clinical data
 ALT (IU/L)†b 22.5 (25.1) 33.0 (50.5) 19 (12.0)
 AST (IU/L)†c 29.0 (24.9) 35.5 (57.5) 22 (11.6)
HIV-status
 Anti-HIV Positive Positive NA
 HIV RNA (copies/ml)† 11,452 (8933) 11,075 (7866) NA
 CD4 cells/μl† 384 (234) 403 (233) NA
 CD8 cells/μl† 936 (394) 850 (517) NA
HCV-status
 Anti-HCV Negative Positive NA
 HCV RNA (log10 IU/ml)
† 0 (0) 6.4 (0.9) NA
HCV genotype
 1b* NA 15 (41.7) NA
 2a* NA 20 (55.6) NA
 Others* NA 1 (2.7) NA
Table 2 Characteristics of  HIV-1-infected MSM recruited 
in the study
†  Mean ± standard deviation (SD)
Characteristics Duration of HIV‑1 infection
1–3 years >3 years
Number 22 13
Age (years)† 30.2 (6.6) 34.5 (7.0)
Deduced infection time (years)† 2.0 (0.6) 5.6 (2.1)
HIV RNA (copies/ml)† 25,611 (30,255) 27,657 (30,144)
CD4 cells/μl† 356 (105) 348 (241)
CD8 cells/μl† 924 (312) 874 (247)
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and anti-CD32 PerCP-eFluor 710 (clone 6C4). All anti-
bodies were purchased from BD Biosciences (San Diego, 
CA, USA) except CD32 from eBiosciences (San Diego, 
CA, USA). Samples were analyzed on BD FACS Fortessa 
(BD Biosciences, San Jose, CA, USA) and the frequencies 
of CD16+ or CD32+ cells in CD56+ T cells, CD56+ NK 
cells and CD56− T cells were calculated and compared.
Image analysis of CD16/CD32 expression
To identify the expression of CD16 and CD32 on CD56+ 
T cells, CD56+ NK cells and CD56− T cells at single-cell 
level, 1  ×  105 PBMC from three healthy controls were 
stained with anti-CD3 Pacific Blue (clone UCHT1), anti-
CD56 PE-Cy7 (clone B159), anti-CD16 APC-Cy7 (clone 
3G8) and anti-CD32 PerCP-eFluor 710 (clone 6C4) and 
were run on an ImageStreamχ MarkII system (Amnis 
Corporation, Seattle, WA, USA). 20,000 events were col-
lected for each sample and single color control was used 
to create a compensation matrix to correct for spectral 
overlap. Collected data were analyzed using IDEAS 3.0 
software (Amnis Corporation, Seattle, WA, USA).
CD56+ T cells sorting
PBMCs were stained with anti-CD3 Pacific Blue (clone 
UCHT1, BD Biosciences), anti-CD56 PE-Cy7 (clone 
B159, BD Biosciences) for 30 min at room temperature. 
CD56+ T cells, CD56+ NK cells and CD56− T cells 
were sorted by BD FACS AriaIII (BD Biosciences, San 
Jose, CA) and only cells with purity >95% were used in 
subsequent experiments.
Activation of purified CD56+ T cells by CD16/CD32 
cross‑linking
1  ×  105 purified CD56+ T cells from healthy controls 
were stimulated with 10  μg/ml of purified anti-CD16 
antibody (clone 3G8, Santz Cruz biotechnology, Santa 
Cruz, CA, USA) or 10 μg/ml purified anti-CD32 antibody 
(clone 3D3, Santz Cruz biotechnology) or mouse IgG1(κ) 
(clone X40, BD Biosciences) isotype control for 30  min 
on ice. Cells were washed to remove unbound antibody 
and incubated with 10  μg/ml of goat anti-mouse IgG1 
F(ab′)2 for 5  h (Santz Cruz biotechnology, Santa Cruz, 
USA) at 37 °C. Cells were washed and stained with anti-
CD3 Pacific Blue (clone UCHT1), anti-CD56 PE-Cy7 
(clone B159) and anti-CD107a PE-Cy5 (clone H4A3) 
and fixed by 2% paraformaldehyde (PFA). All data were 
acquired on BD FACS Fortessa (BD Biosciences, San Jose, 
CA, USA) and analyzed by FlowJo software (Treestar, 
Ashland, OR, USA).
Evaluation of CD56+ T‑mediated nonspecific ADCC activity
The nonspecific ADCC assay was performed as previ-
ously described, in which the mouse mastocytoma cell 
line P815 was used as target cells [27]. Briefly, PBMC 
were stimulated with P815 cells alone or P815 cells/
P815-specific Abs (P815/Abs) complex (1:100 dilu-
tion of polyclonal rabbit anti-mouse lymphocyte serum, 
Accurate Chemical & Scientific Corp., Westbury, NY) 
at an E:T ratio of 10:1. Brefeldin-A (10 μg/ml, Sigma, St 
Louis, MO, USA), GolgiStop (5  μg/ml, BD Biosciences) 
and anti-CD107a PE-Cy5 (clone H4A3, BD Biosciences) 
were added immediately to cell medium and incubated 
for 6 h. Cells were fixed by 2% PFA and stained with anti-
CD3 Pacific Blue (clone UCHT1), anti-CD56 PE-Cy7 
(clone B159), anti-CD16 APC-Cy7 (clone 3G8), anti-
CD4 PE (clone RPA-T4), anti-CD8 APC (clone RPA-T8), 
and anti-IFNγ FITC (clone 25,723.11). To evaluate the 
response time of antibody-dependent response medi-
ated by CD56+ T and NK cells, PBMC were cocultured 
with P815/Abs for 2, 4 and 6 h and fixed and stained as 
above. All data were acquired on BD FACS Fortessa (BD 
Biosciences, San Jose, CA, USA) and analyzed by FlowJo 
software (Treestar, Ashland, OR, USA).
Rapid fluorometric assay to test cytotoxicity mediated 
by CD56+ T cells
Based on methods adapted from a rapid fluorometric 
ADCC (RFADCC) assay [44], 1 × 106 target cells (P815) 
were double-stained with 5  μM PKH-26 (Sigma, St. 
Louis, MO, USA) and 5 μM 5-(and-6)-carboxyfluorescein 
diacetate succinimidyl ester (CFSE) (Molecular Probes, 
Eugene, OR, USA). Purified CD56+ T cells, NK cells and 
T cells were used as effector cells and incubated with 
P815/Abs complex or P815 alone in a microtiter plate 
with an E:T ratio of 1:1. After 10 h incubation, cells were 
washed and fixed in cold 2% paraformaldehyde. Samples 
were run on BD FACS Fortessa (BD Biosciences, San 
Jose, CA, USA) and data were analyzed by FlowJo soft-
ware (Treestar, Ashland, OR, USA).
HIV‑1 specific peptides
HIV-1 gag, pol, env solid-phase peptide pools contain-
ing 20-mers (overlapping by 10 amino acids) from HIV-1 
strain CN54 were synthesized to 95% purity by Bio-Sci-
entific Co., Shanghai, China. Peptides were dissolved to 
a concentration of 1  mg/ml in RPMI 1640 containing 
10% dimethyl sulphoxide (DMSO) as stock solutions, and 
working solutions were obtained by further dilution to a 
final concentration of 1 μg/ml.
CD56+ T‑mediated HIV‑1‑specific ADCC assay
Whole blood samples were incubated with HIV-1 gag, 
pol and env peptide pools respectively at 37  °C for 5  h. 
Brefeldin-A (10  μg/ml, Sigma), GolgiStop (5  μg/ml, BD 
Biosciences) and anti-CD107a APC (clone H4A3, 20 μl/
ml, BD Biosciences) were added immediately to the cell 
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medium and incubated for 6 h. Samples incubated with 
phorbol-12-myristate-13-acetate (PMA) (1  mg/ml) plus 
ionomycin (1 mg/ml) were used as positive controls and 
samples incubated with DMSO (1  mg/ml, Sigma) were 
used as negative controls. Samples were surface-stained 
with live/dead dye Amcyan (Invitrogen, Carlsbad, CA, 
USA), anti-CD3-PerCP (clone SK7) and anti-CD56-PE 
(clone B159), and then lysed, permeabilized and intracel-
lularly stained with anti-IFNγ Alexa Fluor700 (clone B27, 
BD Biosciences) and anti-CD107a APC (clone H4A3). 
All data were acquired on BD FACS Fortessa (BD Bio-
sciences, San Jose, CA, USA) and analyzed by FlowJo 
software (Treestar, Ashland, OR, USA).
ELISA assay
1  ×  105 sorted CD56+ T cells were co-cultured with 
1  ×  105 P815 cells alone, 1  ×  105  P815 cells plus 
P815-specific Abs, or medium alone for 24  h at 37  °C. 
The level of secreted IFNγ in culture supernatants was 
detected by ELISA (cat# 88-7316, eBioscience, San Diego, 
CA, USA) according to the manufacturer’s instruction. 
The sensitivity of the ELISA kit was 4 pg/ml.
Identification of peripheral iNKT cells
Human peripheral invariant NKT (iNKT) cells were 
characterized as CD3+ T cells expressing a spe-
cific TCR (Vα24-Jα18-Vβ11). To identify iNKT cells, 
PBMCs were surface-stained with anti-CD3 Pacific 
Blue (clone UCHT1, BD Biosciences) and anti-
Vα24-Jα18 FITC (clone 6B11, BD Biosciences). CD3+ 
Vα24-Jα18+ double positive cells were defined as 
iNKT cells. To detect CD16, CD161 and CD69 expres-
sion on iNKT and CD56+ T cells, PBMC were surface-
stained with anti-CD3 Pacific Blue, anti-Vα24-Jα18 
FITC (clone 6B11), anti-CD56 PE-Cy7 (clone B159), 
anti-CD16 (clone eBioCB16, eBioscience), anti-CD161 
(clone DX12, BD Biosciences) and anti-CD69 (clone 
FN50, BD Biosciences). Samples were analyzed on BD 
FACS Fortessa (BD Biosciences, San Jose, CA, USA) 
and the frequencies of CD16+ or CD32+ cells in 
CD56+ T cells, CD56+ NK cells and CD56− T cells 
were calculated and compared.
Recovery of impaired antibody‑dependent CD56+ T cell 
responses in HIV+ subjects by MMP inhibitor
1  ×  105 purified DN CD56+ T cells were cultured in 
interleukin-2-supplemented medium in the presence 
or absence of broad-spectrum MMP inhibitor GM6001 
(5 mM) or DMSO for 0, 3, 6 and 12 h. CD16 expression 
(MFI) was detected by flow cytometry at each point. 
Additionally, changes in P815/Ab-stimulated purified 
CD56+ T cell responses (at an E:T ratio of 1:1) following 
GM 6001 (50 μM) (Sigma) treatment was analyzed after 
6 h of coculture. An equivalent volume of DMSO (Sigma) 
was used as control. Cells were washed/stained as 
described above and fixed in cold 2% PFA. All data were 
acquired on BD FACS Fortessa (BD Biosciences, San Jose, 
CA, USA) and analyzed by FlowJo software (Treestar, 
Ashland, OR, USA).
To determine whether GM6001 could restore the 
capacity of dysfunctional CD56+ T cell-medicated 
ADCC in HIV-1 infected subjects, purified DN (CD4-
CD8-) CD56+ T cells were cultured in interleukin-2 
(IL2)-supplemented medium in the presence of 5  μM 
GM6001(Santz Cruz biotechnology, Santa Cruz, CA, 
USA) or an equivalent amount of DMSO vehicle alone. 
The degranulating capacities of CD56+ T cells follow-
ing stimulation with P815 cells or Ab-coated P815 cells 
were analyzed and compared. After stained with anti-
CD107a PE-Cy5 (clone H4A3, BD Biosciences) and anti-
IFNγ FITC (clone 25,723.11, BD Biosciences), cells were 
washed by PBS and fixed by 2% paraformaldehyde (PFA). 
All data were acquired on BD FACS Fortessa and ana-
lyzed by FlowJo software.
Statistical analysis
All the statistical and graphic analyses were performed 
using GraphPad Prism 5.0 (GraphPad Software, La 
Jolla, CA, USA) or Microsoft Excel 2007. Comparisons 
between groups were performed using Mann–Whitney 
U test, nonparametric t test, or Wilcoxon matched-pairs 
signed rank test when necessary. The Spearman’s cor-
relation test was used to evaluate correlations between 
groups. All P values were two-tailed and considered sig-
nificant when lower than 0.05.
Additional files
Additional file 1: Figure S1. Purity detection of sorted CD56+ T cells. 
CD56+ T cells were sorted by BD FACSAriaIII and detected for purity with 
BD FACS Fortessa. The figure showed a representative result for purity test 
(96.4%).
Additional file 2: Figure S2. Comparison of the response time of 
non-specific ADCC mediated by CD56+ T and CD56+ NK cells. a Levels 
of CD107a expression and IFNγ production were detected from CD56+ 
T cells and CD56+ NK cells incubated with P815 plus Abs for 2, 4, 6 h 
by flow cytometry. b Comparison of the frequencies of CD107a+ cells 
and IFNγ+ cells between CD56+ T cells and CD56+ NK cells in different 
responding time (n = 10).
Additional file 3: Figure S3. Comparison of the TCR-dependent 
responses mediated by CD56+ T and CD56− T cells. a PBMC cells from 
HIV-1-infected patients were activated by env, gag and pol peptides for 
6 h. SEB activation and medium alone were set as positive and negative 
controls respectively. Intracellular IFNγ production was detected from acti-
vated CD56+ T cells and CD56− T cells by flow cytometry. b Comparison 
of the frequencies of IFNγ+ cells between activated CD56+ T cells and 
CD56− T cells from HIV-1-infected patients (n = 10).
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